Suraksha
Clinic & Diagnostics

Date: 12 August 2026

To

The Secretary	The Secretary
BSE Limited	**The National Stock Exchange of India Limited**
Phiroze Jeejeebhoy Towers	Exchange Plaza, Plot No. C/1. G Block
Dalal Street	Bandra -Kurla Complex, Bandra (East)
Mumbai - 400 001	Mumbai- 400 051
Scrip Code: 544293	**Scrip Symbol : SURAKSHA**

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Press release in respect of unaudited (standalone and consolidated) financial results of the Company for quarter ended 30 June 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited (standalone and consolidated) financial results of the Company for quarter ended 30 June 2026.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated 14 July 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under:

Date of occurrence of Event/Information: 12 August 2026
Time of occurrence of Event/Information: 04:30 P.M. (IST)

This may please be informed to all the concerned.

For Suraksha Diagnostic Limited

RITU MITTAL

Digitally signed by RITU MITTAL
Date: 2026.08.12 17:01:24 +05'30'

Ritu Mittal
Joint Managing Director & CEO
DIN: 00165886

Encl.: as above

Suraksha Diagnostic Limited
(Formerly known as Suraksha Diagnostic Private Limited)
CIN: L85110WB2005PLC102265
Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I **Website:** www.surakshanet.com
Phone:(033) 6605 9750

Suraksha Diagnostics Delivers Strong Q1 FY27 Performance

PAT grew by 40% year-on-year and
EBITDA grew by 28% year-on-year

Kolkata, 12th Aug 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter ended 30th June 2026.

Q1 FY27 Financial Performance Snapshot (Y-o-Y)

Total Income	EBITDA	Profit After Tax	EPS
₹ 887 million	₹ 315 million	₹ 128 million	₹ 2.5
+21%	**+28%**	**+40%**	**₹ 0.70**

Key Financial Highlights

Particulars	Q1 FY27	Q1 FY26	*Y-o-Y*	FY26	FY25	*Y-o-Y*
Total Income (₹ million)	887.33	734.92	20.7%	3135.78	2559.39	22.5%
EBTIDA (₹ million)	315.30	246.56	27.9%	985.58	850.88	15.8%
EBTIDA Margin (%)	36.0%	34.0%		31.8%	33.8%	
PAT (₹ million)	128.45	91.75	40.0%	314.04	309.78	1.4%
PAT Margin (%)	14.7%	12.6%		10.1%	12.3%	

Key Operational Highlights

Particulars	Q1 FY27	Q1 FY26	*Y-o-Y*	FY26	FY25	*Y-o-Y*
Total tests (# million)	2.10	1.92	8.9%	8.16	6.68	22.0%
Total Patients (# million)	0.38	0.33	12.1%	1.37	1.19	14.9%
Tests per patient (#)	5.56	5.72	-2.8%	5.95	5.60	6.2%
Average Revenue per test (₹)	418	377	10.6%	381	377	0.9%
Average Revenue per patient (₹)	2,321	2,101	10.5%	2,264	2,113	7.1%

Commenting on the results Mrs. Ritu Mittal, Joint Managing Director & CEO said, -

"Suraksha has started FY27 on a strong note, delivering healthy growth across both volumes and realisations. Revenue grew 21% YoY in Q1 FY27, with EBITDA increasing 28% and PAT growing 40%, supported by an improvement in EBITDA margin to 36.0%.

The quarter witnessed healthy growth in both patient and test volumes, reflecting continued strength in underlying consumer demand. This was complemented by healthy realisation growth, supporting a strong overall performance during the quarter.

We continued to expand our network during the quarter, commissioning one hub and three spoke centres, in line with our strategy of building clusters and progressively increasing density around them. We remain focused on strengthening our presence across existing and new markets while maintaining a disciplined approach to expansion.

Suraksha Genomics continued its strong growth trajectory, delivering revenue growth of 136% YoY in Q1 FY27, marking the fifth consecutive quarter of sequential growth. While still at an early stage, we believe genomics has the potential to emerge as an increasingly meaningful contributor to our business over the coming years."

About Suraksha Diagnostic Limited:

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar and Assam.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 4 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centres are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: MUFG Intime India Private Limited
Email: investors@surakshanet.com	Name: Mr. Omkar Bagwe Email: omkar.bagwe@in.mpms.mufg.com
CIN: L85110WB2005PLC102265	Name: Sumeet Khaitan Email: Sumeet.khaitan@in.mpms.mufg.com
Website: https://www.surakshanet.com/	Meeting Request Link – Click Here

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.